Pelthos Therapeutics Inc. (PTHS) News
Follow Pelthos Therapeutics Inc. (PTHS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Pelthos Therapeutics reports Q2 2026 revenue growth on Zelsuvmi demand
Pelthos Therapeutics said second-quarter 2026 net product revenue rose to $15.4 million from $10.7 million in Q1, as Zelsuvmi prescription units increased 48% to 11,925.
EARNINGS | Aug 13, 2026, 01:20 PM UTC
L
Pelthos Therapeutics reports second-quarter 2026 financial results
Pelthos Therapeutics (PTHS) announces its second-quarter 2026 financial results, with no EPS, revenue, or guidance figures provided in the feed.
EARNINGS | Aug 13, 2026, 11:10 AM UTC
L
PTHS - Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
PTHS - Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
EARNINGS | Aug 03, 2026, 12:01 PM UTC
L
Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes
Pelthos Therapeutics Inc. (NYSE: PTHS ), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company was added as a memb
EQUITY | Jun 30, 2026, 08:17 PM UTC